Finally, axonal sprouting and the formation of new corticocortical connections occur after focal cortical infarcts. 8,9 Thus, it is reasonable to presume that pharmacological agents that Background and Purpose-New insights into the brain's ability to reorganize after injury are beginning to suggest novel restorative therapy targets. Potential therapies include pharmacological agents designed to promote axonal growth. The purpose of this study was to test the efficacy of one such drug, GSK249320, a monoclonal antibody that blocks the axon outgrowth inhibition molecule, myelin-associated glycoprotein, to facilitate recovery of motor skills in a nonhuman primate model of ischemic cortical damage. Methods-Using a between-groups repeated-measures design, squirrel monkeys were randomized to 1 of 2 groups: an experimental group received intravenous GSK249320 beginning 24 hours after an ischemic infarct in motor cortex with repeated dosages given at 1-week intervals for 6 weeks and a control group received only the vehicle at matched time periods. The primary end point was a motor performance index based on a distal forelimb reach-and-retrieval task. Neurophysiological mapping techniques were used to determine changes in spared motor representations. Results-All monkeys recovered to baseline motor performance levels by postinfarct day 16. Functional recovery in the experimental group was significantly facilitated on the primary end point, albeit using slower movements. At 7 weeks post infarct, motor maps in the spared ventral premotor cortex in the experimental group decreased in area compared with the control group. Conclusions-GSK249320, initiated 24 hours after a focal cortical ischemic infarct, facilitated functional recovery. Together with the neurophysiological data, these results suggest that GSK249320 has a substantial biological effect on spared cortical tissue. However, its mechanisms of action may be widespread and not strictly limited to peri-infarct cortex and nearby premotor areas.
P harmacological treatments to improve functional outcomes after stroke remain limited beyond the use of thrombolytic agents during the first few hours. As our understanding of regenerative mechanisms that underlie the recovery of function matures, it is expected that approaches to target long-term recovery will receive increasing attention. 1 This study focuses on GSK249320, a monoclonal antibody that blocks the axon outgrowth inhibition molecule, myelin-associated glycoprotein (MAG). Brain levels of MAG spontaneously increase after a stroke. 2 The putative mechanism of action for this MAG antibody is the disinhibition of neurite sprouting and growth, thus allowing new neuronal connections to be formed. 3 Many neurophysiological and neuroanatomical events related to behavioral recovery have been described in the days to weeks after a stroke. After focal ischemic infarct in primary motor cortex (M1) in both rodents and nonhuman primates, motor representations in spared cortical areas undergo functional reorganization in parallel with motor recovery. 4, 5 Furthermore, growth-promoting and growth-inhibiting genes are upregulated in spared neural tissue both adjacent to the infarct and in more remote areas connected with infarct. 2, 6, 7 promote neurite sprouting and growth might amplify these events and thereby increase the extent of behavioral recovery during this period.
Previous studies in rodents have demonstrated that a MAG antibody can neutralize MAG-mediated inhibition and promote neurite outgrowth associated with improved behavioral recovery after injury to the cerebral cortex. 3, 10 A study in 47 healthy human subjects found GSK249320 to be well tolerated in doses ≤25 mg/kg body weight. 11 A recent clinical trial enrolled 42 patients 24 to 72 hours after stroke onset and found GSK249320 to be safe. 12 The primary goal of this study was to evaluate the efficacy of GSK249320 for enhancing recovery of skilled use of the forelimb in a nonhuman primate model of focal cortical ischemia and to determine whether its effects are evident in the organization of movement representations in spared cortical areas.
Methods
Nine adult male squirrel monkeys were used in this study. All experiments were conducted in accordance with institutional and federal guidelines for care and use of experimental animals and with approval from the Institutional Animal Care and Use Committee. A procedural timeline is presented in Figure 1 . Monkeys were assigned randomly to 1 of 2 groups, differing only with regard to whether they received postinfarct injections of GSK249320 (experimental group) or vehicle (control group). One investigator was wholly responsible for animal behavioral training and postinfarct testing and was blind to the treatment condition. Each monkey underwent preinfarct training on a pellet retrieval task for 10 days, and then probe trials were conducted once per week for 2 weeks. 13 Next, monkeys underwent the first of 2 surgical procedures. In the first procedure, the distal forelimb (DFL) representations in primary motor cortex (M1), dorsal premotor cortex (PMd), and ventral premotor cortex (PMv), as well as the surrounding proximal representations, were identified by intracortical microstimulation mapping techniques. Then, a cortical infarct that targeted 80% of the M1 DFL was created by electrocoagulation of surface vasculature ( Figure 2 ). After recovery from anesthesia, monkeys were returned to their home cages.
The active drug, identified as GSK249320 and supplied by GSK, United Kingdom, is an antibody to MAG. It binds with human MAG or its monkey ortholog with similar affinity (data on file). GSK249320 (30 mg/kg per dose; experimental group) or vehicle (control group) was administered intravenously every 7 days for 7 weeks, beginning 24 hours after infarct. Postinfarct behavioral performance on the retrieval task was assessed weekly on days after the injections. Then, in a second surgical procedure, intracortical microstimulation mapping was repeated to verify the extent of the infarct and to determine whether motor representations were altered. After a 2-week survival period, animals were humanely euthanized and the brains were removed for histological analysis.
The primary end point was a function of the number of finger flexions required to retrieve a pellet (flexions per retrieval performance index) measured during probe sessions. Secondary end points included retrieval success rate, time required to perform different phases of the retrieval task, and frequency of aiming errors, again measured during the probe sessions. Statistical tests included repeated-measures ANOVA and Bonferroni post hoc comparisons maintaining α-level at 0.05. Group averages are reported as mean+SEM. Additional details can be found in the online-only Data Supplement.
Results

Infarct Size and Location
The mean extent of the infarct across the cortical surface was 12.03±1.04 mm2 in the experimental group and 10.97±1.07 mm 2 in the control group. There was no statistically significant difference between groups in the absolute lesion size: t (5) =0.69; P=0.52 ( Figure 3 ). The M1 DFL damage relative to each monkey's baseline DFL was 81.5±1.61% for the experimental group and 79.1+0.98% for the control group, closely in line with our 80% target ( Figure 2 ). There was no statistically significant difference between groups in the relative lesion size: t (5) =1.136; P=0.31. As intended, all infarcts spared DFLs at the rostral edge of the M1 DFL, as well as a small portion located medial and lateral to the infarct region. No damage was evident in PMd or PMv.
Behavioral Assessment of Skilled Hand Use
There was a significant effect of group (F [1, 5] =12.732; P=0.001), time (F [8, 40] =15.696; P<0.0001), and group X time interaction (F [8, 40] =5.899; P<0.0001) in the primary end point, flexions per retrieval performance index. Bonferroni multiple comparison tests revealed significant group differences on days 3 (t [1, 40] =6.95; P=0.009) and 9 (t [1, 40] =3.86; P=0.018). That is, performance was better in the experimental group on day 3 (experimental group=1.55+0.22; control group=3.44+0.73) and day 9 (experimental group=1.01+0.06; control group=1.92+0.60). On day 3, there was no overlap between the groups. There were no differences between groups before the infarct or on day 16 through 44 ( Figure 4A ).
With respect to secondary end points, there was a significant effect of group (F [1, 5] Figure 4B ). Assessing reach and retrieval times separately, there was a significant effect of time for both reach (F [3, 15] =8.217; P=0.0018) and retrieval (F [3, 15] =12.904; P=0.0002) but there was no effect of group nor group X time interaction. Bonferroni comparisons indicate that time to reach was significantly greater on day 3 than on preinfarct day 1 (t [1, 15] There was also a significant effect of time for aiming errors (F [3, 15] =12.904; P=0.0028). Bonferroni comparisons indicated that the average aiming errors for all monkeys were greater than preinfarct measures on days 3 and 9. There was no significant effect of group nor group X time interaction in aiming errors: day 3 versus preinfarct day 1 (t [1, 15] =3.0; P=0.054) and preinfarct day 2 (t [1, 15] =3.60; P=0.0156). Day 9 versus preinfarct day 1 (t [1, 15] =3.60; P=0.0156) and preinfarct day 2 (t [1, 15] =3.626; P=0.0150). Days 3 and 9 were not significantly different: (t [1, 15] =0.022; P>0.9999).
Postinfarct Changes in Spared Motor Representations
Forelimb movements typically were evoked throughout the peri-infarct M1, PMd DFL, and PMv DFL at low current levels ( Figure 2 ). In addition, forelimb movements could be evoked from sites along the border of the infarcted territory. However, because these sites were typically no >250 µm from the border and current thresholds were relatively high (often 25-30 µA), these sites were eliminated from the analyses because the evoked movements were likely due to current spread into the spared tissue. In 3 of the intracortical microstimulation mapping procedures, proximal but not DFL movements were evoked in PMd (baseline maps: Exp-3, Cont-3; postinfarct maps: Cont-3). This lack of distal movements at threshold current levels is not unusual in PMd of squirrel monkeys, and thus, these data were retained for the statistical analyses. DFL movements were observed at threshold currents in each of the PMv mapping procedures.
Area means (±SEM) for the DFLs before and after the infarct are presented in Table. In the peri-infarct M1 DFL, there were no statistically significant differences between groups (group effect: F(1,5=0.0068, P=0.9374; time effect: F(1,5)=2.0365, P=0.2129; group X time interaction: F(1,5)=0.21374, P=0.6633). In the PMd DFL, there were no statistically significant differences between groups (group effect: F [1, 5] =2.7294, P=0.1594; time effect: F [1, 5] =3.0600, P=0.1407; group X time interaction: F [1, 5] =1.0144, P=0.3601). It should be noted though that PMd DFL increased in each of the 4 monkeys in the experimental group but in only one of the 3 monkeys in the control group (χ 2 =9.561; P=0.002). In PMv, there was no group (F [1, 5] =0.5553; P=0.4897) nor time effect (F[1,5]=0.1821; P=0.6873), but there was a significant group X time interaction (F[1,5]=11.0953; P=0.0208). Bonferroni multiple comparison tests revealed a decrease in PMv DFL in the experimental group after the infarct (experimental preversus experimental postinfarct area), but this difference was not significant [t(1,5)=2.87; P=0.07]. There was also no significant difference between the pre-and post control group maps (t[1,5]=1.92; P=0.112; Figure 5 ). . Left, Vascular pattern with superimposed movement representations in M1, dorsal premotor cortex (PMd), and ventral premotor cortex (PMv). M1 DFL (≈80%) was targeted for the infarct based on intracortical microstimulation (ICMS) maps of evoked movements (movement coding: red=digit; green=wrist/forearm; purple=proximal+wrist/forearm; yellow=digit+wrist; and grey=proximal). Dashed white line indicates intended infarct territory. In the case illustrated here, a large vein that bisected the DFL was intentionally spared but not its branches. White box encloses the enlarged region shown in middle and right images. Middle, Ischemic region in M1 DFL several minutes after the infarct was completed. The ischemic area is readily distinguishable because of blanching of the tissue. Visual glare is because of the presence of saline on the brain surface during the procedure. This infarct technique produces sharply defined borders between ischemic and normally perfused tissue (indicated by blue boundary) and creates an infarct through all 6 layers of cerebral cortex but spares the underlying white matter. Right, Photograph of ischemic region 7 weeks after the infarct in M1 DFL. As intended, the perimeter of the M1 DFL, as well as PMd and PMv (not shown), was spared by the infarct, as evidenced by ICMS-evoked movements. Scale bar, 500 µm. Because of the significant interaction effect in PMv and the potential for differential effects between PMv and PMd in experimental versus control groups, we also examined PMv-PMd difference scores. A 2-way ANOVA revealed a significant group X time interaction (F [1, 5] =8.75; P=0.0308). Bonferroni adjusted multiple comparisons showed that for the experimental group, the baseline PMv-PMd difference scores were greater than the postinfarct difference scores (t [1, 5] =3.678; P=0.0286). There was no prepost difference in PMv-PMd difference scores for the control group (t [1, 5] =0.7557; P=0.9678).
Discussion
Loss of function after stroke is due not only to the local ischemic damage, but also to a large extent, a disconnection of functional neural networks throughout the brain. Therefore, investigations into various therapeutic strategies to improve motor function after stroke have targeted interventions thought to promote neural reorganization, restoring functional connectivity within the spared motor networks. Many recent restorative therapies have targeted myelin-associated axon outgrowth inhibition molecules, inhibitors that promote a nonpermissive growth environment after stroke, reducing neurite outgrowth, 14,15 thus constraining neural plasticity and limiting recovery. 16 One current putative intervention strategy is to neutralize such inhibition, thereby promoting axonal growth and sprouting to restore movement-related communication in cortical networks. Of the various myelin-associated inhibitors, MAG is of interest as it has been shown to be upregulated in peri-infarct tissue after ischemic damage in the aged brain. 2 This study examined the efficacy of a new monoclonal antibody, GSK 249320, to MAG (ie, MAG antibody) in squirrel monkeys for recovery after an ischemic infarct in M1. A pilot experiment conducted before this study demonstrated that after cortical infarcts in M1 of squirrel monkeys, MAG antibody was present within the infarcted tissue within hours after a single administration ( Figure I in the online-only Data Supplement).
With an infarct targeting of 80% of the M1 DFL, the deficit was transient in both groups. However, GSK249320, initiated intravenously 24 hours after the infarct, facilitated more rapid recovery of DFL motor function, including the primary end point, flexions per retrieval performance index. The experimental group demonstrated superior motor performance on the reach-and-retrieval task on day 3 (2 days after initial treatment) and day 9 (1 day after second treatment). In fact, the deficit was unusually mild in the experimental group even on day 3. This rapid recovery in motor skill is somewhat surprising given the putative effects of MAG antibody on axonal growth promotion. However, evidence from other studies suggests that, in addition to blocking MAG-mediated inhibition of neurite outgrowth, treatment with MAG antibody protects oligodendrocytes from oxidative-stress induced cell death. 3 Because oligodendrocytes play a critical role in axonal integrity and are particularly sensitive to ischemic injury, 17, 18 it is possible that treatment with GSK249320 in this study exerted its therapeutic benefits through protection of oligodendrocytes in the vicinity of the infarct. There is also evidence suggesting that MAG antibody may enhance synaptic plasticity. In the mature central nervous system, MAG receptors, such as NgR1 (part of the Nogo receptor family), maintain synaptic stability by inhibiting dendritic changes in morphology and function, such as long-term potentiation. 19, 20 Blocking these pre-and postsynaptic inhibitory receptors could account for an immediate activity-dependent modulation of synaptic connections supporting a rapid increase in functional recovery.
Comparing neurophysiological map changes revealed unexpected findings. Given that MAG is known to be upregulated in peri-infarct cortex, 2 it might be expected that GSK249320 would have its greatest effect in the 20% of the Figure 5 ). On the basis of our previous studies demonstrating an increase in PMv DFL after M1 infarct in squirrel monkeys not subjected to postinfarct intervention, 5, 8 we expected to see postinfarct expansions in both groups but larger increases in the experimental group. We have also shown in a recent study that spared premotor representations expand as a function of rehabilitative training in a rat model of ischemic infarct. 4 As expected, in this study, PMv DFL increased in size in each of the 3 control monkeys but decreased in size in each of the 4 experimental monkeys. On the basis of our historical data, 5, 8 the expected increase in PMv DFL in animals with an 80% infarct in the M1 DFL, but no rehabilitative training, is 33.4% at 3 months post infarct. In this study, the increase in PMv DFL representation in the control group was 17.5% at 7 weeks post infarct. Furthermore, we have shown in other studies that after M1 lesions, spared motor maps first decrease and then increase in size with increasing time after infarct. 4, 21 Given the longer survival times in the historical controls, the size of the increase in PMv DFL in control monkeys in this study is within the expected range. However, in the experimental group, PMv maps decreased by 19.2%. We have only observed decreases in PMv DFL when infarcts were <50% of the M1 DFL 8 or were derived at much earlier time points after the infarct (<3 weeks). 4, 22 Because there is no evidence that GSK249320 affected lesion size, this result suggests that the drug treatment may have had an unusual effect on cortical motor networks to support recovery of DFL performance compared with what is typically observed during spontaneous recovery alone.
One possible explanation for the discrepant map results in PMv is that monkeys in the experimental group used a particularly successful compensatory reaching strategy. Although movement kinematics were not explicitly examined in this study, some support for a successful compensatory strategy in the experimental group can be derived from examination of the secondary behavioral end point, time in well. Although monkeys in the experimental group demonstrated superior scores on the flexions per retrieval performance index, they also spent more time with their digit(s) in the food well to perform retrievals on day 3. It is possible that slower and more deliberate movements were part of a compensatory strategy that facilitated improvement. Furthermore, if monkeys in the experimental group differentially used proximal arm and shoulder muscles for reaching or stabilization, recovery may have been accompanied by an expansion of proximal forelimb representations at the expense of distal representations in PMv. Consistent with this hypothesis, examination of Figure 5 reveals that at many specific sites, intracortical microstimulation resulted in distal movements in the preinfarct map but proximal movements in the postinfarct map. This observation is most evident in the experimental group. Previous studies from this laboratory using a similar infarct model have shown that a variety of compensatory strategies are used soon after the infarct. The kinematic patterns that are eventually used after recovery often are different than those used before the infarct. 23 Alternatively, compensatory strategies could involve attentional or motivational mechanisms related to a more focused effort leading to more successful retrievals.
In a virtual lesion study in healthy humans using transcranial magnetic stimulation, Davare et al 24 provided evidence for a functional dissociation between PMd and PMv. Their results supported the view that PMv is involved more in the grasping component of a grip-lift task, whereas PMd is involved more in the lifting phase, recruiting more proximal muscles. If the trend toward larger distal representations in PMd and smaller distal representations in PMv with GSK249320 treatment is borne out in larger samples, then it is reasonable to suggest that the differential functional specialization of premotor areas in precision grasping is altered by postinfarct GSK249320. We propose that reorganization of spared cortical networks results in a functional rebalancing of premotor cortical areas, so that PMd assumes a greater role in the grasp phase and PMv in the lift-retrieval phase of the task. In the context of the previous literature, the present results narrow the range of possibilities for the mechanisms underlying the functional benefits of GSK249320. Plasticity in peri-infarct M1 DFL is an unlikely candidate, unless a different neurophysiological or neuroanatomical end point is needed to capture the effect of GSK249320. It is likely that compensatory kinematic or attentional strategies, supported by plasticity in premotor cortical areas, contributed to faster recovery in the experimental group. The best case can be made for plasticity in PMv, although PMd is still a potential site. In the future, larger studies should (1) expand on the present results to examine other premotor areas (PMd and the supplementary motor area) and (2) focus on kinematic end points. It would also be interesting to know whether GSK249320 given to normal monkeys would affect the motor map representations in PMv and PMd similarly to what we have shown in the experimental group. As plasticity after neural injury is likely to be a network response, it is also possible that subcortical or contralateral structures are involved. However, it is clear that GSK249320 is safe in a nonhuman primate model of focal cortical ischemia, accelerates functional recovery, and has a significant effect on the neurophysiology of spared motor representations.
SUPPLEMENTAL MATERIAL
Supplemental Methods
Overview
Nine adult male squirrel monkeys (Worldwide Primates, Inc., Miami, FL; Genus: Saimiri; >3 years old; weight range: 837 -1,179 g) were used in the present study. All experiments were conducted in accordance with institutional (Kansas University Medical Center) and federal (National Institutes of Health) guidelines for care and use of experimental animals and with approval from the Institutional Animal Care and Use Committee. Monkeys were housed in a climate-controlled vivarium maintaining ambient temperatures between 24 0 C and 28 0 C and relative humidity between 30% and 70%. Food (Purina Lab Diet #5088) was provided twice daily (supplemented with fruit and vegetables) and water was provided ad libitum through an automatic watering system. On days when behavior was assessed, feeding was scheduled after assessment (see behavioral methods). Routine health checks were made daily by Laboratory Animal Resource staff under supervision of institutional veterinary staff.
Monkeys were assigned randomly to one of two groups, differing only with regard to whether they received post-infarct injections of GSK249320 (Experimental or Exp group) or vehicle (Control or Cont group). Each monkey underwent pre-infarct training on a pellet retrieval task for 10 days to establish a proficient, but not maximized performance level. After the training period, but before surgical procedures, probe trial sessions were conducted on the retrieval task once/week for two weeks. Next, monkeys underwent the first of two surgical procedures. In the first procedure, the distal forelimb representations (DFLs) in primary motor cortex (M1), dorsal premotor cortex (PMd) and ventral premotor cortex (PMv), as well as the surrounding proximal representations were identified by intracortical microstimulation (ICMS) mapping techniques. Then, a cortical infarct that targeted the M1 DFL was created by electrocoagulation of surface vasculature. After recovery from anesthesia, monkeys were returned to their home cages. GSK249320 (Exp group) or vehicle (Cont group) was administered intravenously every seven days for seven weeks, beginning 24 hr after infarct. Post-infarct behavioral performance on the retrieval task was assessed weekly on days following the injections. Then, in a second surgical procedure, ICMS mapping was repeated to verify the extent of the infarct, and to determine if motor representations were altered. At the conclusion of the ICMS mapping procedures, a neuronal tract-tracer was injected into the DFL in PMv. After a two-week survival period, animals were humanely euthanized and the brains removed for histological analysis.
Blinding procedures
To minimize experimenter bias, one investigator was wholly responsible for animal behavioral training and post-infarct testing, and was blind to the treatment condition. A second investigator was wholly responsible for random assignment of monkeys to experimental groups and for preparation and injection of the drug or vehicle. During cortical mapping sessions, ICMS-evoked responses were defined by other investigators blind to the treatment condition.
Behavioral procedures
All behavioral testing and training was conducted using a modified Klüver board apparatus. 1 This device consisted of a Plexiglas board attached to the front of the monkey's home cage, with five food wells drilled into its surface. Each well was 5mm in depth and varied in diameter from 25-9.5 mm (designated wells 1-5 respectively). The behavioral task consisted of reaching through the cage bars, inserting one or more fingers into a well, and retrieving a 1 single, small food pellet (45 mg; BioServe, Flemington NJ). Pellets were placed one at a time into one of the five food wells in a randomized block design (i.e., equal number of trials for each well). Behavioral sessions were videotaped for later analysis.
Experimental time periods are referenced to the number of days or weeks relative to the infarct; i.e., Week -6 (minus 6) = six weeks prior to infarct, Day 7 = seven days after infarct. Throughout the behavioral phase of these experiments (Weeks -6 through 7), monkeys were maintained on a controlled food schedule, such that they were provided a total daily amount of food (pellets during behavioral testing/training + laboratory chow after behavioral testing/training) equal to 3% of their ad libitum body weight. This amount of food is adequate to maintain a stable body weight over time. On training and testing days, the number of pellets consumed was tallied, and supplemental food provided as needed to reach the 3% value.
Hand (distal forelimb) preference testing . Monkeys were required to retrieve 100 food pellets from the Klüver board (20 trials/well). Testing was conducted over a minimum of two days (maximum 50 trials/day). The animal was free to use either hand to perform the task. Based on the number of reaches and retrievals made with each hand, the monkey's hand preference was defined as the hand used on more than 50% of trials.
Pre-infarct training phase . Pre-infarct training was conducted using each monkey's preferred distal forelimb five days per week for a total of ten days. Each training session consisted of a 25 trial probe session followed immediately by a 30 minute training session. The probe session consisted of randomized presentation of pellets into one of the five wells until a total of five trials per well was performed. The training session consisted of trials conducted in only one or two wells, depending on the training day. Training began on the largest well on Day -35 and progressed to the smallest well according to the following schedule: Day -35, 100% well 1; Day -34, 100% well 2; Day -33, 100% well 3; Day -32, 50% well 3 and 50% well 4; Day -31, 100% well 4; Day -28, 50% well 4 and 50% well 5; Day -27-to-24, 100% well 5. The strategy was to provide exposure to all wells, with an emphasis on increasingly more difficult wells, but avoiding overtraining on any individual well.
Pre-infarct baseline testing (
Week -3 to -2). Monkeys were given 50 probe trials (10 trials per well) once per week to determine baseline performance. (Week 1-7) . Monkeys were tested once per week during a 50 trial probe session (10 trials per well). Testing began on Day 3, then weekly on Day 9, 16, 23, 30, 37, and 44. Lack of appetite and motivation associated with surgical recovery precluded reliable testing on Day 1-2. Thus, post-infarct testing occurred on the day following drug/vehicle injections, except for Week 1, when testing occurred two days following drug/vehicle.
Post-infarct testing
Surgical procedures
Monkeys were sedated with an initial dose of ketamine (20 mg, i.m.) followed by atropine (0.054mg, i.m.). Supplemental doses were given as needed as the monkeys were weighed and examined in preparation for the surgical procedure. The scalp, arm (opposite the hemisphere to be mapped) and leg (for catheterization) were shaved and cleaned. The trachea was treated with a local anesthetic (20% benzocaine spray and 2% lidocaine jelly) and intubated (2.5-3.0 mm i.d. tube). Gas anesthesia was then introduced (1.5% to 3% halothane -75% nitrous oxide), and the saphenous vein catheterized with a 24g angiocath for delivery of lactated Ringers with 3% dextrose (10ml/kg/hr) and other required fluids. Ophthalmic ointment was liberally applied to the corneas and the monkey placed into a stereotaxic frame. The incision area was
Analysis of behavioral performance
All behavioral performance metrics were analyzed from slow-motion and frame-byframe playback of the time-stamped video records. Because monkeys typically vary in their preinfarct performance levels (at least without substantial overtraining), normalized scores were used to reduce the influence of pre-infarct baseline performance. This is especially important in non-human primate studies in which large sample sizes are not feasible. Therefore, we utilized a normalized performance index as the ratio of the raw performance score for each session to the average of the pre-infarct baseline scores (raw performance score ÷ average baseline performance).
The primary endpoint was a function of the number of finger flexions required to retrieve a pellet (flexions per retrieval performance index) measured during probe sessions on all five wells. Secondary endpoints included retrieval success rate, time required to perform different phases of the retrieval task, and frequency of aiming errors, again measured during the probe sessions on all five wells.
Flexions per retrieval. Flexions per retrieval were calculated for each probe session by dividing the total number of times that the digits flexed in an attempt to grasp the pellet divided by the total number of successful retrievals. The flexions per retrieval score thus provided a reliable metric of digital dexterity, with lower scores indicating better performance. A flexions per retrieval performance index was calculated by dividing scores on each post-infarct day by the average score from the two baseline testing sessions.
Retrieval time. Retrieval time was defined as the amount of time (in seconds) required for the entire reach and retrieval sequence, including time to propel the distal forelimb to the board (reach time), time that the distal forelimb was in contact with the board (time on board), time that the digits were within the well (well time), and time to retract the distal forelimb back into the cage (retraction time). More specifically, reach began when the digits crossed the plane of the cage bars and ended when they either first contacted the surface of the Klüver board or the food well. Time on board began when the digits first contacted the board surface ended when one or more of the digits entered the target well. Time in well began when one or more of the digits entered the target well and ended when the digits were no longer contacting the well and a pellet was successfully retrieved. Retraction time began when the digit emerged from the well and ended when the distal forelimb crossed the plane of the cage bars. For simplicity, times were analyzed only for trials in which the monkey performed a complete movement sequence that included only one finger flexion to successfully remove the pellet from the well. To normalize retrieval times relative to each individual animal's pre-injury levels, a retrieval time index was calculated by dividing retrieval times on each post-infarct day by the average retrieval time from the two baseline testing sessions. Thus, the reported retrieval time index is unitless.
Aiming errors. A failure to insert the fingers directly into the well was defined as an aiming error. For each monkey, the percentage of aiming errors per session was calculated and normalized to the average of baseline performance as described for retrieval data.
Analysis of ICMS maps
A computer algorithm was used to unambiguously delineate functional boundaries for analysis of representational areas. 1 Distal forelimb maps were analyzed in peri-infarct M1, PMd and PMv separately.
Statistical analysis
Statistical analyses were performed using JMP v10.0 (SAS Institute, Inc. Cary NC). Statistical tests included repeated-measures ANOVA and Bonferroni post-hoc comparisons. Group averages are reported as Mean + SEM.
Attrition
Two monkeys, one in the Exp group and one in the Cont group, died during the experimental period. Neither of these two monkeys had received GSK249320. One monkey died of acute respiratory and cardiac failure during the first surgical procedure (Exp group), and the other monkey died approximately two weeks after the first procedure (Cont group). This monkey had received two injections of the vehicle (24hrs and 1week post-infarct). Necropsy revealed mild enteritis and pneumonitis, but the cause of death was not conclusive. Of the remaining seven monkeys, four were injected with MAG antibody (Exp group) and three were given
Supplemental Figures
Supplemental Figure Legend I . Histological verification of infarct and immunohistochemical staining for Anti-MAG at the level of M1 in a squirrel monkey. Results are derived from a pilot experiment prior to the full study. In the case illustrated here, MAG antibody (37mg/kg) was given to a squirrel monkey 24 hours after an ischemic infarct targeting 80% of the distal hand
